NF-κB hijacking theranostic Pt(ll) complex in cancer therapy
暂无分享,去创建一个
G. Battaglia | Xiaohe Tian | Mingzhu Zhang | Qiong Zhang | Martin R. Gill | Cesare de Pace | Yingzhong Zhu | Lei Luo | Hong-ping Zhou | Jieying Wu | Yu-peng Tian
[1] Xianghuo He,et al. Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma , 2018, Theranostics.
[2] Ming Yan,et al. Cancer-associated Fibroblast-derived IL-6 Promotes Head and Neck Cancer Progression via the Osteopontin-NF-kappa B Signaling Pathway , 2018, Theranostics.
[3] Xiaohe Tian,et al. Mild acidic-enhanced mitochondrial-targeting by a neutral thiophene based terpyridine molecule with large two-photon action cross-section , 2017 .
[4] M. Yaffe,et al. Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. , 2017, Journal of the American Chemical Society.
[5] Ren-Shyan Liu,et al. STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer , 2017, Theranostics.
[6] J. Sessler,et al. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. , 2016, Angewandte Chemie.
[7] A. Schintlmeister,et al. Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney , 2016, Chemical science.
[8] E. Cummins,et al. The role of HIF in immunity and inflammation. , 2016, Molecular aspects of medicine.
[9] S. Lippard,et al. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.
[10] N. Russo,et al. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs. , 2016, Inorganic chemistry.
[11] Chengcheng Zhu,et al. Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells , 2016, Chemical science.
[12] M. Bianchi,et al. NF-κB oscillations translate into functionally related patterns of gene expression , 2016, eLife.
[13] Xiaoyong Wang,et al. Functionalization of Platinum Complexes for Biomedical Applications. , 2015, Accounts of chemical research.
[14] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Tianfeng Chen,et al. Luminescent platinum(ii) complexes with self-assembly and anti-cancer properties: hydrogel, pH dependent emission color and sustained-release properties under physiological conditions , 2015, Chemical science.
[16] L. De Cola,et al. When self-assembly meets biology: luminescent platinum complexes for imaging applications. , 2014, Chemical Society reviews.
[17] Jun Lin,et al. In vivo multimodality imaging and cancer therapy by near-infrared light-triggered trans-platinum pro-drug-conjugated upconverison nanoparticles. , 2013, Journal of the American Chemical Society.
[18] Justin J. Wilson,et al. Synthetic methods for the preparation of platinum anticancer complexes. , 2013, Chemical reviews.
[19] V. Rodríguez,et al. Anticancer cyclometalated complexes of platinum group metals and gold , 2013 .
[20] C. Che,et al. Luminescent organoplatinum(II) complexes containing bis(N-heterocyclic carbene) ligands selectively target the endoplasmic reticulum and induce potent photo-toxicity. , 2013, Chemical communications.
[21] G. Lahav,et al. Encoding and Decoding Cellular Information through Signaling Dynamics , 2013, Cell.
[22] J. López-Novoa,et al. Subcellular targets of cisplatin cytotoxicity: an integrated view. , 2012, Pharmacology & therapeutics.
[23] G. Rimbach,et al. Curcumin--from molecule to biological function. , 2012, Angewandte Chemie.
[24] C. Leung,et al. Inhibition of TNF-α stimulated nuclear factor-kappa B (NF-κB) activation by cyclometalated platinum(II) complexes. , 2012, Chemical communications.
[25] S. Ghosh,et al. NF-κB in immunobiology , 2011, Cell Research.
[26] Sunil Krishnan,et al. Targeting inflammatory pathways for tumor radiosensitization. , 2010, Biochemical pharmacology.
[27] M. Tomicic,et al. Cisplatin resistance: preclinical findings and clinical implications. , 2010, Biochimica et biophysica acta.
[28] C. Smythe,et al. A ruthenium(II) polypyridyl complex for direct imaging of DNA structure in living cells. , 2009, Nature chemistry.
[29] M. Pasparakis,et al. Regulation of tissue homeostasis by NF-κB signalling: implications for inflammatory diseases , 2009, Nature Reviews Immunology.
[30] Xiaoren Zhang,et al. NF-κB Signaling Pathway, Inflammation and Colorectal Cancer , 2009, Cellular and Molecular Immunology.
[31] Matthew S. Hayden,et al. New regulators of NF-κB in inflammation , 2008, Nature Reviews Immunology.
[32] L. Kèlland,et al. The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.
[33] J. Yates,et al. Adaptation of energy metabolism in breast cancer brain metastases. , 2007, Cancer research.
[34] Chi-Ming Che,et al. Structures, photoluminescence, and reversible vapoluminescence properties of neutral platinum(II) complexes containing extended pi-conjugated cyclometalated ligands. , 2006, Journal of the American Chemical Society.
[35] K. To,et al. Platinum‐based anticancer agents: Innovative design strategies and biological perspectives , 2003, Medicinal research reviews.
[36] R. P. Tang,et al. Syntheses, Electronic Absorption, Emission, and Ion‐Binding Studies of Platinum(II) C^N^C and Terpyridyl Complexes Containing Crown Ether Pendants , 2002 .
[37] Miles A. Miller,et al. Tumor associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2016 .
[38] M. Karin,et al. Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.
[39] Y. Song,et al. NF‐κB as a potential molecular target for cancer therapy , 2007 .